Literature DB >> 29299411

Reproducibility of PD-L1 assessment in non-small cell lung cancer-know your limits but never stop trying to exceed them.

Marius Ilie1,2,3, Paul Hofman1,2,3.   

Abstract

Entities:  

Year:  2017        PMID： 29299411      PMCID： PMC5750161          DOI： 10.21037/tlcr.2017.10.13

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  19 in total

Review 1.  Adaptive Immune Resistance: How Cancer Protects from Immune Attack.

Authors:  Antoni Ribas
Journal:  Cancer Discov       Date:  2015-08-13       Impact factor: 39.397

Review 2.  Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients.

Authors:  Marius Ilie; Véronique Hofman; Manfred Dietel; Jean-Charles Soria; Paul Hofman
Journal:  Virchows Arch       Date:  2016-02-25       Impact factor: 4.064

3.  Intra- and Interobserver Reproducibility Assessment of PD-L1 Biomarker in Non-Small Cell Lung Cancer.

Authors:  Wendy A Cooper; Prudence A Russell; Maya Cherian; Edwina E Duhig; David Godbolt; Peter J Jessup; Christine Khoo; Connull Leslie; Annabelle Mahar; David F Moffat; Vanathi Sivasubramaniam; Celine Faure; Alena Reznichenko; Amanda Grattan; Stephen B Fox
Journal:  Clin Cancer Res       Date:  2017-04-18       Impact factor: 12.531

4.  PD-L1 immunohistochemistry in clinical diagnostics of lung cancer: inter-pathologist variability is higher than assay variability.

Authors:  Hans Brunnström; Anna Johansson; Sofia Westbom-Fremer; Max Backman; Dijana Djureinovic; Annika Patthey; Martin Isaksson-Mettävainio; Miklos Gulyas; Patrick Micke
Journal:  Mod Pathol       Date:  2017-06-30       Impact factor: 7.842

5.  PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma.

Authors:  Wendy A Cooper; Thang Tran; Ricardo E Vilain; Jason Madore; Christina I Selinger; Maija Kohonen-Corish; PoYee Yip; Bing Yu; Sandra A O'Toole; Brian C McCaughan; Jennifer H Yearley; Lisa G Horvath; Steven Kao; Michael Boyer; Richard A Scolyer
Journal:  Lung Cancer       Date:  2015-05-18       Impact factor: 5.705

6.  PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project.

Authors:  Fred R Hirsch; Abigail McElhinny; Dave Stanforth; James Ranger-Moore; Malinka Jansson; Karina Kulangara; William Richardson; Penny Towne; Debra Hanks; Bharathi Vennapusa; Amita Mistry; Rasika Kalamegham; Steve Averbuch; James Novotny; Eric Rubin; Kenneth Emancipator; Ian McCaffery; J Andrew Williams; Jill Walker; John Longshore; Ming Sound Tsao; Keith M Kerr
Journal:  J Thorac Oncol       Date:  2016-11-29       Impact factor: 15.609

7.  Interlaboratory concordance of PD-L1 immunohistochemistry for non-small-cell lung cancer.

Authors:  Andreas H Scheel; Gudrun Baenfer; Gustavo Baretton; Manfred Dietel; Rolf Diezko; Thomas Henkel; Lukas C Heukamp; Bharat Jasani; Korinna Jöhrens; Thomas Kirchner; Felix Lasitschka; Iver Petersen; Simone Reu; Hans-Ulrich Schildhaus; Peter Schirmacher; Kristina Schwamborn; Ulrich Sommer; Oliver Stoss; Markus Tiemann; Arne Warth; Wilko Weichert; Jürgen Wolf; Reinhard Büttner; Josef Rüschoff
Journal:  Histopathology       Date:  2017-11-21       Impact factor: 5.087

8.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors:  Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer
Journal:  N Engl J Med       Date:  2015-09-27       Impact factor: 91.245

9.  Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas.

Authors:  Andreas H Scheel; Manfred Dietel; Lukas C Heukamp; Korinna Jöhrens; Thomas Kirchner; Simone Reu; Josef Rüschoff; Hans-Ulrich Schildhaus; Peter Schirmacher; Markus Tiemann; Arne Warth; Wilko Weichert; Rieke N Fischer; Jürgen Wolf; Reinhard Buettner
Journal:  Mod Pathol       Date:  2016-07-08       Impact factor: 7.842

10.  Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer.

Authors:  Therese Phillips; Pauline Simmons; Hector D Inzunza; John Cogswell; James Novotny; Clive Taylor; Xiaoling Zhang
Journal:  Appl Immunohistochem Mol Morphol       Date:  2015-09
View more
  7 in total

1.  Implementation of PD-L1 22C3 IHC pharmDxTM in Cell Block Preparations of Lung Cancer: Concordance with Surgical Resections and Technical Validation of CytoLyt® Prefixation.

Authors:  Si Kei Lou; Hyang Mi Ko; Tomonari Kinoshita; Scott MacDonald; Jessica Weiss; Katarzyna Czarnecka-Kujawa; Scott L Boerner; Kazuhiro Yasufuku; Ming-Sound Tsao; Joerg Schwock
Journal:  Acta Cytol       Date:  2020-06-29       Impact factor: 2.319

2.  First-line immunotherapy for patients with advanced stage or metastatic non-small cell lung cancer…finally what threshold of PD-L1 expression on tumor cells?

Authors:  Paul Hofman
Journal:  Transl Lung Cancer Res       Date:  2019-10

3.  Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients.

Authors:  Marius Ilié; Mélanie Ngo-Mai; Elodie Long-Mira; Sandra Lassalle; Catherine Butori; Coraline Bence; Marame Hamila; Véronique Hofman; Paul Hofman
Journal:  J Vis Exp       Date:  2018-09-25       Impact factor: 1.355

4.  PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN.

Authors:  Toni K Choueiri; Sabina Signoretti; Abdallah Flaifel; Wanling Xie; David A Braun; Miriam Ficial; Ziad Bakouny; Amin H Nassar; Rebecca B Jennings; Bernard Escudier; Daniel J George; Robert J Motzer; Michael J Morris; Thomas Powles; Evelyn Wang; Ying Huang; Gordon J Freeman
Journal:  Clin Cancer Res       Date:  2019-08-01       Impact factor: 12.531

5.  Transcriptional and post-transcriptional regulation of checkpoint genes on the tumour side of the immunological synapse.

Authors:  Paula Dobosz; Przemysław A Stempor; Miguel Ramírez Moreno; Natalia A Bulgakova
Journal:  Heredity (Edinb)       Date:  2022-04-22       Impact factor: 3.832

Review 6.  Multiplex Immunofluorescence and Multispectral Imaging: Forming the Basis of a Clinical Test Platform for Immuno-Oncology.

Authors:  Clifford C Hoyt
Journal:  Front Mol Biosci       Date:  2021-06-02

7.  Prospective evaluation of EBUS-TBNA specimens for programmed death-ligand 1 expression in non-small cell lung cancer patients: a pilot study.

Authors:  Juliana Guarize; Elena Guerini Rocco; Filippo de Marinis; Giulia Sedda; Luca Bertolaccini; Stefano Maria Donghi; Monica Casiraghi; Clementina Di Tonno; Massimo Barberis; Lorenzo Spaggiari
Journal:  J Bras Pneumol       Date:  2021-07-12       Impact factor: 2.624
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.